Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
Company has received more than 570,000 samples since launching its COVID-19 testing services in 2020 for skilled nursing homes, businesses, college campuses, health care facilities, and other venues SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Biocept, Inc .
View HTML
Toggle Summary Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
Company’s ultra-sensitive and quantitative assays support efforts to develop targeted therapies for cancers driven by a variety of genetic mutations SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, will present data
View HTML
Toggle Summary Biocept to Present at Four Virtual Investor Conferences in September
SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall , President and CEO, will present at four upcoming investor conferences as follows: H.C. Wainwright 23 rd Annual Global Investment
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.
View HTML
Toggle Summary Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
Study to be presented at the Society for Neuro-Oncology Third Annual Conference on Brain Metastases, Aug. 19-20 SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s
View HTML
Toggle Summary Biocept Reports Second Quarter 2021 Financial Results
Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users Issued coverage with high-value payment by Medicare for the
View HTML
Toggle Summary Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021
SAN DIEGO --(BUSINESS WIRE)--Aug. 9, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021 .
View HTML
Toggle Summary Biocept Names David Karlander as Senior Vice President of Commercial Operations
SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed David Karlander as Senior Vice President of Commercial Operations. With more than 25 years of industry experience, Karlander will lead all
View HTML
Toggle Summary Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells
Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which
View HTML
Toggle Summary Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman
Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testing SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to
View HTML